JP2023552583A5 - - Google Patents
Info
- Publication number
- JP2023552583A5 JP2023552583A5 JP2023535063A JP2023535063A JP2023552583A5 JP 2023552583 A5 JP2023552583 A5 JP 2023552583A5 JP 2023535063 A JP2023535063 A JP 2023535063A JP 2023535063 A JP2023535063 A JP 2023535063A JP 2023552583 A5 JP2023552583 A5 JP 2023552583A5
- Authority
- JP
- Japan
- Prior art keywords
- formula
- compound
- salt
- solvate
- prevention
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20213020.9 | 2020-12-10 | ||
| EP20213020 | 2020-12-10 | ||
| PCT/EP2021/084987 WO2022122914A1 (en) | 2020-12-10 | 2021-12-09 | Substituted pyrazolo piperidine carboxylic acids |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023552583A JP2023552583A (ja) | 2023-12-18 |
| JP2023552583A5 true JP2023552583A5 (enExample) | 2024-12-10 |
Family
ID=73793025
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023535063A Pending JP2023552583A (ja) | 2020-12-10 | 2021-12-09 | 置換されたピラゾロピペリジンカルボン酸類 |
Country Status (31)
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4011873A1 (en) * | 2020-12-10 | 2022-06-15 | Bayer Aktiengesellschaft | Substituted pyrazolo piperidine carboxylic acids |
| EP4011874A1 (en) * | 2020-12-10 | 2022-06-15 | Bayer Aktiengesellschaft | Substituted pyrazolo piperidine carboxylic acids |
| EP4536205A1 (en) | 2022-06-09 | 2025-04-16 | Bayer Aktiengesellschaft | Soluble guanylate cyclase activators for use in the treatment of heart failure with preserved ejection fraction in women |
| WO2024163561A1 (en) * | 2023-01-31 | 2024-08-08 | Invivosciences, Inc. | Systems and methods for treating heart failure with preserved ejection fraction |
| WO2025067414A1 (zh) * | 2023-09-27 | 2025-04-03 | 海思科医药集团股份有限公司 | 吡唑羧酸衍生物及其在医药上的应用 |
| WO2025162280A1 (zh) * | 2024-01-30 | 2025-08-07 | 海思科医药集团股份有限公司 | 吡唑羧酸衍生物及其在医药上的应用 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19834044A1 (de) | 1998-07-29 | 2000-02-03 | Bayer Ag | Neue substituierte Pyrazolderivate |
| DE19834047A1 (de) | 1998-07-29 | 2000-02-03 | Bayer Ag | Substituierte Pyrazolderivate |
| DE19943639A1 (de) | 1999-09-13 | 2001-03-15 | Bayer Ag | Dicarbonsäurederivate mit neuartigen pharmazeutischen Eigenschaften |
| DE19943636A1 (de) | 1999-09-13 | 2001-03-15 | Bayer Ag | Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften |
| DE19943634A1 (de) | 1999-09-13 | 2001-04-12 | Bayer Ag | Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften |
| DE19943635A1 (de) | 1999-09-13 | 2001-03-15 | Bayer Ag | Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften |
| AR031176A1 (es) | 2000-11-22 | 2003-09-10 | Bayer Ag | Nuevos derivados de pirazolpiridina sustituidos con piridina |
| DE10110750A1 (de) | 2001-03-07 | 2002-09-12 | Bayer Ag | Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften |
| DE10110749A1 (de) | 2001-03-07 | 2002-09-12 | Bayer Ag | Substituierte Aminodicarbonsäurederivate |
| DE10220570A1 (de) | 2002-05-08 | 2003-11-20 | Bayer Ag | Carbamat-substituierte Pyrazolopyridine |
| BRPI0816382A2 (pt) * | 2007-09-06 | 2015-02-24 | Merck Sharp & Dohme | Composto, composição, e, métodos para ativar a guanilato ciclase solúvel e para tratar ou previnir doenças |
| DE102010001064A1 (de) | 2009-03-18 | 2010-09-23 | Bayer Schering Pharma Aktiengesellschaft | Substituierte 2-Acetamido-5-Aryl-1,2,4-triazolone und deren Verwendung |
| UA109650C2 (xx) | 2010-02-27 | 2015-09-25 | Біс-арилзв'язані арилтриазолони та їх застосування | |
| DE102010021637A1 (de) | 2010-05-26 | 2011-12-01 | Bayer Schering Pharma Aktiengesellschaft | Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung |
| EA201390060A1 (ru) | 2010-07-09 | 2013-07-30 | Байер Интеллектуэль Проперти Гмбх | Аннелированные пиримидины и триазины и их применение для лечения и/или профилактики сердечно-сосудистых заболеваний |
| DE102010040233A1 (de) | 2010-09-03 | 2012-03-08 | Bayer Schering Pharma Aktiengesellschaft | Bicyclische Aza-Heterocyclen und ihre Verwendung |
| EP2632551B1 (en) * | 2010-10-28 | 2016-07-06 | Merck Sharp & Dohme Corp. | Soluble guanylate cyclase activators |
| DE102010043379A1 (de) | 2010-11-04 | 2012-05-10 | Bayer Schering Pharma Aktiengesellschaft | Substituierte 6-Fluor-1H-Pyrazolo[4,3-b]pyridine und ihre Verwendung |
| DE102011007272A1 (de) | 2011-04-13 | 2012-10-18 | Bayer Pharma Aktiengesellschaft | Verzweigte 3-Phenylpropionsäure-Derivate und ihre Verwendung |
| HRP20191755T1 (hr) * | 2012-09-07 | 2019-12-27 | Boehringer Ingelheim International Gmbh | Alkoksipirazoli kao aktivatori topljive gvanilat ciklaze |
| WO2015095515A1 (en) * | 2013-12-20 | 2015-06-25 | Novartis Ag | Sgc activators for the treatment of glaucoma |
| SI3215498T1 (sl) | 2014-11-03 | 2018-11-30 | Bayer Pharma Aktiengesellschaft | Hidroksialkil-substituirani derivati feniltriazola in njihove uporabe |
| GB201705263D0 (en) * | 2017-03-31 | 2017-05-17 | Probiodrug Ag | Novel inhibitors |
| CN116829545A (zh) * | 2020-12-10 | 2023-09-29 | 拜耳公司 | 取代的吡唑基哌啶羧酸 |
| AU2021398486A1 (en) * | 2020-12-10 | 2023-06-22 | Bayer Aktiengesellschaft | The use of sgc activators for the treatment of ophthalmologic diseases |
-
2021
- 2021-12-09 AR ARP210103422A patent/AR124297A1/es unknown
- 2021-12-09 RS RS20241357A patent/RS66294B1/sr unknown
- 2021-12-09 SI SI202130234T patent/SI4259617T1/sl unknown
- 2021-12-09 AU AU2021393988A patent/AU2021393988A1/en active Pending
- 2021-12-09 KR KR1020237022818A patent/KR20230118144A/ko active Pending
- 2021-12-09 PL PL21823605.7T patent/PL4259617T3/pl unknown
- 2021-12-09 WO PCT/EP2021/084987 patent/WO2022122914A1/en not_active Ceased
- 2021-12-09 LT LTEPPCT/EP2021/084987T patent/LT4259617T/lt unknown
- 2021-12-09 EP EP21823605.7A patent/EP4259617B1/en active Active
- 2021-12-09 GE GEAP202316287A patent/GEAP202316287A/en unknown
- 2021-12-09 GE GEAP202116287A patent/GEP20247649B/en unknown
- 2021-12-09 JP JP2023535063A patent/JP2023552583A/ja active Pending
- 2021-12-09 PE PE2023001808A patent/PE20231501A1/es unknown
- 2021-12-09 TW TW110146019A patent/TW202237589A/zh unknown
- 2021-12-09 DK DK21823605.7T patent/DK4259617T3/da active
- 2021-12-09 ES ES21823605T patent/ES2997117T3/es active Active
- 2021-12-09 MX MX2023006903A patent/MX2023006903A/es unknown
- 2021-12-09 HR HRP20241543TT patent/HRP20241543T1/hr unknown
- 2021-12-09 PT PT218236057T patent/PT4259617T/pt unknown
- 2021-12-09 CR CR20230242A patent/CR20230242A/es unknown
- 2021-12-09 US US18/256,647 patent/US20240051935A1/en active Pending
- 2021-12-09 IL IL303296A patent/IL303296A/en unknown
- 2021-12-09 FI FIEP21823605.7T patent/FI4259617T3/fi active
- 2021-12-09 CA CA3204495A patent/CA3204495A1/en active Pending
- 2021-12-09 CN CN202180081892.0A patent/CN116710439A/zh active Pending
- 2021-12-09 HU HUE21823605A patent/HUE069255T2/hu unknown
-
2023
- 2023-06-01 EC ECSENADI202340828A patent/ECSP23040828A/es unknown
- 2023-06-02 CO CONC2023/0007335A patent/CO2023007335A2/es unknown
- 2023-06-06 CL CL2023001632A patent/CL2023001632A1/es unknown
- 2023-06-07 SA SA523441083A patent/SA523441083B1/ar unknown
- 2023-06-07 DO DO2023000115A patent/DOP2023000115A/es unknown
- 2023-06-08 JO JOJO/P/2023/0132A patent/JOP20230132A1/ar unknown